Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
45.88%
Operating Margin
27.50%
Net Margin
18.37%
Efficiency Metrics
Revenue per Expense Ratio
1.38
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
64.94%
Income Tax Rate
23.91%
EPS
7.2600000000
Balance Sheet Analysis
Current Ratio
3.03
Cash Ratio
1.80
Working Capital
$507.70M
Debt to Equity
3.35
Debt to Assets
67.33%
Equity Ratio
20.07%
Cash Flow Analysis
Operating Cash Flow Ratio
36.88%
Free Cash Flow Ratio
-81.13%
CapEx to Revenue
118.01%
Dividends Paid
$80.60M
Stock Buybacks
$2.60M
Total Shareholder Returns
$83.20M
Cash Position Change
48.29%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 4.34%
Detailed Growth Metrics
Core Performance
Revenue
10.83%
Net Income
111.94%
EPS
110.43%
Operating Income
767.81%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
9.08%
Operating Cash Flow
-2.46%
Free Cash Flow
-58.47%
Balance Sheet Health
Assets
12.45%
Debt
13.71%
Book Value per Share
11.05%
Inventory
22.92%
Shareholder Returns
Dividends per Share
4.34%
Shares Outstanding
0.85%
Long Term Trends
3Y Revenue/Share
14.39%
5Y Revenue/Share
9.19%
3Y Dividend/Share
11.30%
5Y Dividend/Share
22.50%